Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in the United States, is renowned for its innovative therapies in the field of rare diseases. Founded in 1992, Alexion has made significant strides in developing life-changing treatments, particularly in the areas of neurology, nephrology, and immunology. The company’s flagship products, including Soliris and Ultomiris, are unique in their ability to target complement-mediated diseases, setting new standards in patient care. With a strong market position, Alexion has achieved notable milestones, such as expanding its global reach across North America, Europe, and Asia. Committed to advancing science and improving patient outcomes, Alexion Pharmaceuticals continues to be a pivotal player in the biopharmaceutical industry.
DitchCarbon Score
How does Alexion Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alexion Pharmaceuticals, Inc.'s score of 93 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alexion Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary of AstraZeneca PLC, any climate commitments or emissions data may be inherited from its parent company. AstraZeneca has set ambitious climate targets, which include commitments to reduce greenhouse gas emissions across its operations. These targets are cascaded to Alexion Pharmaceuticals, reflecting a broader corporate strategy aimed at sustainability and climate resilience. While specific reduction targets for Alexion are not detailed, AstraZeneca's initiatives include participation in the Science Based Targets initiative (SBTi) and commitments to renewable energy through the RE100 initiative. These efforts underscore a commitment to reducing Scope 1, 2, and 3 emissions, although specific figures for Alexion are not disclosed. In summary, while Alexion Pharmaceuticals, Inc. does not currently report its own emissions data, it aligns with the climate commitments and reduction strategies of its parent company, AstraZeneca PLC, focusing on sustainability and emissions reduction across the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 298,498,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 322,319,000 | 000,000,000 | 000,000,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alexion Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
